Cwm LLC Has $1.71 Million Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

Cwm LLC raised its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 550.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 8,105 shares of the company’s stock after purchasing an additional 6,859 shares during the period. Cwm LLC’s holdings in Inspire Medical Systems were worth $1,711,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SouthState Corp bought a new stake in shares of Inspire Medical Systems in the 2nd quarter worth $27,000. GAMMA Investing LLC boosted its holdings in Inspire Medical Systems by 559.3% during the third quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock worth $38,000 after purchasing an additional 151 shares during the last quarter. Quarry LP grew its position in Inspire Medical Systems by 105.4% in the 2nd quarter. Quarry LP now owns 343 shares of the company’s stock worth $46,000 after purchasing an additional 176 shares in the last quarter. Daiwa Securities Group Inc. purchased a new stake in Inspire Medical Systems in the 2nd quarter valued at about $53,000. Finally, Van ECK Associates Corp lifted its position in shares of Inspire Medical Systems by 7.5% during the 2nd quarter. Van ECK Associates Corp now owns 1,029 shares of the company’s stock worth $138,000 after buying an additional 72 shares in the last quarter. 94.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on INSP. Truist Financial reaffirmed a “buy” rating and issued a $240.00 target price (up from $217.00) on shares of Inspire Medical Systems in a report on Monday, September 30th. Morgan Stanley decreased their target price on Inspire Medical Systems from $250.00 to $210.00 and set an “overweight” rating for the company in a research report on Monday, July 15th. KeyCorp lowered their target price on Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Royal Bank of Canada restated an “outperform” rating and set a $260.00 price objective on shares of Inspire Medical Systems in a report on Wednesday, August 7th. Finally, Leerink Partners boosted their target price on shares of Inspire Medical Systems from $167.00 to $197.00 and gave the company a “market perform” rating in a research note on Tuesday, September 10th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Inspire Medical Systems presently has a consensus rating of “Moderate Buy” and a consensus price target of $216.62.

Inspire Medical Systems Trading Down 5.5 %

INSP opened at $198.91 on Wednesday. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $257.40. The company has a market cap of $5.91 billion, a PE ratio of -361.65 and a beta of 1.34. The company has a 50 day moving average of $199.38 and a 200 day moving average of $182.86.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.46. Inspire Medical Systems had a return on equity of 1.03% and a net margin of 0.85%. The firm had revenue of $195.89 million during the quarter, compared to analyst estimates of $189.08 million. During the same period last year, the company earned ($0.41) earnings per share. The business’s revenue for the quarter was up 29.6% on a year-over-year basis. Research analysts forecast that Inspire Medical Systems, Inc. will post 0.75 earnings per share for the current fiscal year.

Insider Buying and Selling at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 800 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $220.00, for a total value of $176,000.00. Following the sale, the director now directly owns 23,140 shares of the company’s stock, valued at approximately $5,090,800. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Randy Ban sold 4,861 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $188.55, for a total transaction of $916,541.55. Following the completion of the transaction, the insider now directly owns 3,056 shares in the company, valued at $576,208.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Shawn Mccormick sold 800 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $220.00, for a total value of $176,000.00. Following the completion of the sale, the director now owns 23,140 shares in the company, valued at $5,090,800. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,692 shares of company stock valued at $1,099,207 in the last quarter. 4.10% of the stock is currently owned by corporate insiders.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.